Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CARA |
---|---|---|
09:32 ET | 8176 | 0.73 |
09:38 ET | 835 | 0.74 |
09:39 ET | 100 | 0.7252 |
09:41 ET | 100 | 0.725 |
09:43 ET | 100 | 0.725 |
09:45 ET | 100 | 0.725 |
09:48 ET | 200 | 0.7446 |
09:50 ET | 300 | 0.744 |
09:52 ET | 300 | 0.74 |
09:54 ET | 100 | 0.735 |
09:59 ET | 100 | 0.73 |
10:03 ET | 500 | 0.737249 |
10:06 ET | 400 | 0.7305 |
10:08 ET | 200 | 0.731 |
10:10 ET | 984 | 0.736 |
10:12 ET | 18977 | 0.731 |
10:17 ET | 2475 | 0.740099 |
10:19 ET | 300 | 0.7426 |
10:26 ET | 449 | 0.7404 |
10:32 ET | 491 | 0.7403 |
10:39 ET | 200 | 0.7403 |
10:42 ET | 100 | 0.7425 |
10:44 ET | 418 | 0.745 |
10:48 ET | 2343 | 0.745 |
10:51 ET | 100 | 0.74 |
10:53 ET | 100 | 0.74 |
10:55 ET | 100 | 0.74 |
10:57 ET | 100 | 0.7446 |
11:02 ET | 422 | 0.7375 |
11:04 ET | 100 | 0.74 |
11:06 ET | 115 | 0.7398 |
11:09 ET | 500 | 0.735 |
11:11 ET | 1119 | 0.735 |
11:20 ET | 800 | 0.725 |
11:22 ET | 201 | 0.73 |
11:24 ET | 100 | 0.73 |
11:26 ET | 100 | 0.73 |
11:29 ET | 200 | 0.7304 |
11:31 ET | 100 | 0.7304 |
11:36 ET | 100 | 0.731 |
11:38 ET | 200 | 0.7304 |
11:40 ET | 100 | 0.7304 |
11:44 ET | 1011 | 0.7304 |
11:45 ET | 200 | 0.7304 |
11:47 ET | 100 | 0.7304 |
11:49 ET | 4302 | 0.73 |
11:56 ET | 110 | 0.73715 |
11:58 ET | 100 | 0.73 |
12:00 ET | 11007 | 0.725 |
12:02 ET | 100 | 0.725 |
12:03 ET | 4300 | 0.725 |
12:05 ET | 100 | 0.725 |
12:07 ET | 100 | 0.7225 |
12:09 ET | 899 | 0.72 |
12:12 ET | 1673 | 0.7234 |
12:14 ET | 100 | 0.72 |
12:16 ET | 1249 | 0.7364 |
12:18 ET | 200 | 0.721 |
12:20 ET | 300 | 0.7225 |
12:23 ET | 1099 | 0.7225 |
12:25 ET | 200 | 0.7225 |
12:30 ET | 100 | 0.7225 |
12:36 ET | 900 | 0.72 |
12:38 ET | 700 | 0.72 |
12:41 ET | 200 | 0.72 |
12:43 ET | 400 | 0.7298 |
12:45 ET | 635 | 0.721 |
12:50 ET | 1000 | 0.7393 |
12:54 ET | 100 | 0.721 |
12:56 ET | 400 | 0.722 |
12:57 ET | 200 | 0.722 |
01:01 ET | 585 | 0.721 |
01:03 ET | 581 | 0.721 |
01:06 ET | 600 | 0.726 |
01:08 ET | 23838 | 0.721 |
01:12 ET | 200 | 0.721 |
01:14 ET | 600 | 0.72125 |
01:17 ET | 100 | 0.72125 |
01:21 ET | 200 | 0.72125 |
01:24 ET | 100 | 0.721 |
01:28 ET | 200 | 0.721 |
01:30 ET | 300 | 0.721 |
01:33 ET | 100 | 0.72125 |
01:35 ET | 414 | 0.72125 |
01:37 ET | 11300 | 0.722 |
01:46 ET | 100 | 0.734 |
01:51 ET | 200 | 0.72785 |
01:55 ET | 4100 | 0.722 |
01:57 ET | 800 | 0.73 |
02:00 ET | 100 | 0.732 |
02:02 ET | 100 | 0.73 |
02:04 ET | 4131 | 0.7354 |
02:09 ET | 700 | 0.7387 |
02:11 ET | 500 | 0.735 |
02:13 ET | 1500 | 0.735 |
02:15 ET | 100 | 0.7335 |
02:18 ET | 1411 | 0.735 |
02:20 ET | 2200 | 0.7377 |
02:26 ET | 100 | 0.738838 |
02:29 ET | 200 | 0.7399 |
02:31 ET | 900 | 0.7399 |
02:33 ET | 100 | 0.7338 |
02:36 ET | 200 | 0.7338 |
02:38 ET | 8000 | 0.74125 |
02:45 ET | 310 | 0.7421 |
02:47 ET | 1442 | 0.7434 |
02:51 ET | 1061 | 0.74315 |
02:54 ET | 347 | 0.7433 |
02:56 ET | 125 | 0.7432 |
03:02 ET | 3300 | 0.7405 |
03:05 ET | 149 | 0.7432 |
03:12 ET | 200 | 0.74 |
03:16 ET | 19878 | 0.740353 |
03:18 ET | 146 | 0.7405 |
03:21 ET | 337 | 0.74 |
03:23 ET | 1100 | 0.7401 |
03:25 ET | 2818 | 0.74 |
03:27 ET | 24411 | 0.7371 |
03:30 ET | 3216 | 0.7399 |
03:32 ET | 200 | 0.7216 |
03:34 ET | 700 | 0.7225 |
03:36 ET | 900 | 0.7385 |
03:38 ET | 500 | 0.7301 |
03:39 ET | 100 | 0.725 |
03:41 ET | 710 | 0.725 |
03:43 ET | 773 | 0.73 |
03:45 ET | 1019 | 0.725 |
03:48 ET | 1100 | 0.7216 |
03:50 ET | 5303 | 0.7216 |
03:52 ET | 1128 | 0.72185 |
03:54 ET | 14223 | 0.7267 |
03:56 ET | 24081 | 0.7438 |
03:57 ET | 16447 | 0.7525 |
03:59 ET | 21847 | 0.7503 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Cara Therapeutics Inc | 39.1M | -0.3x | --- |
ImmuCell Corp | 42.6M | -7.1x | --- |
Aadi Bioscience Inc | 43.7M | -0.7x | --- |
Prenetics Global Ltd | 72.3M | -1.4x | --- |
Viaderma Inc | 10.6M | 0.0x | --- |
SQZ Biotechnologies Co | 781.5K | 0.0x | --- |
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $39.1M |
---|---|
Revenue (TTM) | $21.0M |
Shares Outstanding | 54.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.81 |
EPS | $-2.19 |
Book Value | $1.05 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 1.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -579.43% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.